open access

Vol 89, No 4 (2021)
Review paper
Published online: 2021-09-02
Submitted: 2021-03-06
Accepted: 2021-05-23
Get Citation

Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature

Muhammad Waleed Chaudhry1, Syed Muhammad Zubair2, Ali Bin Sarwar Zubairi2, Muhammad Irfan2
DOI: 10.5603/ARM.a2021.0088
·
Pubmed: 34494244
·
Adv Respir Med 2021;89(4):413-418.
Affiliations
  1. Medical Student, Aga Khan Medical College, Karachi, Pakistan
  2. Section of Pulmonary Medicine, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan

open access

Vol 89, No 4 (2021)
REVIEWS
Published online: 2021-09-02
Submitted: 2021-03-06
Accepted: 2021-05-23

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected almost every country in the world since De-cember 2019. Despite the efforts of the human race to combat the virus, we are still looking for an evidence-based permanent cure for the disease. Ivermectin has recently emerged as one of the therapies having a beneficial effect on COVID-19. Ivermectin, owing to its properties, continues to be a possible treatment against the COVID-19 disease. Already being a mainstream drug with minimal adverse effects, it garners valid consideration. It’s use in hospitalized patients, randomized controlled trials, and observational studies has also supported its implementation. In this article, we have reviewed recent studies and explored the effectiveness of ivermectin in hospitalized COVID-19 patients.

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected almost every country in the world since De-cember 2019. Despite the efforts of the human race to combat the virus, we are still looking for an evidence-based permanent cure for the disease. Ivermectin has recently emerged as one of the therapies having a beneficial effect on COVID-19. Ivermectin, owing to its properties, continues to be a possible treatment against the COVID-19 disease. Already being a mainstream drug with minimal adverse effects, it garners valid consideration. It’s use in hospitalized patients, randomized controlled trials, and observational studies has also supported its implementation. In this article, we have reviewed recent studies and explored the effectiveness of ivermectin in hospitalized COVID-19 patients.

Get Citation

Keywords

ivermectin, COVID-19, SARS-CoV-2, virus, treatment, therapy

About this article
Title

Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature

Journal

Advances in Respiratory Medicine

Issue

Vol 89, No 4 (2021)

Article type

Review paper

Pages

413-418

Published online

2021-09-02

DOI

10.5603/ARM.a2021.0088

Pubmed

34494244

Bibliographic record

Adv Respir Med 2021;89(4):413-418.

Keywords

ivermectin
COVID-19
SARS-CoV-2
virus
treatment
therapy

Authors

Muhammad Waleed Chaudhry
Syed Muhammad Zubair
Ali Bin Sarwar Zubairi
Muhammad Irfan

References (43)
  1. World Health Organization. Weekly epidemiological update — 23 February 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update---23-february-2021 (5.03.2021).
  2. Hongchao P, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for COVID-19: interim WHO solidarity trial results. N Engl J Med. 2021; 384(6): 497–511.
  3. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020; 6(10): 1192–1198.
  4. Hermine O, Mariette X, Tharaux PL, et al. CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021; 181(1): 32–40.
  5. Agarwal A, Mukherjee A, Kumar G, et al. PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020; 371: m3939.
  6. Gul MH, Htun ZM, Shaukat N, et al. Potential specific therapies in COVID-19. Ther Adv Respir Dis. 2020; 14: 1753466620926853.
  7. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020; 50(SI-1): 620–632.
  8. Horby P, Lim WS, Emberson JR, et al. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021; 384(8): 693–704.
  9. Crump A, Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011; 87(2): 13–28.
  10. Martin RE, Donahue MJ. Correlation of myosin light chain phosphorylation and gamma aminobutyric acid receptors in Ascaris suum muscle. Comp Biochem Physiol C Comp Pharmacol Toxicol. 1987; 87(1): 23–29.
  11. Sharun K, Dhama K, Patel SK, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020; 19(1): 23.
  12. Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020; 177: 104760.
  13. Wang X, Lv C, Ji X, et al. Ivermectin treatment inhibits the replication of Porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets. Virus Res. 2019; 263: 80–86.
  14. Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178: 104787.
  15. Abdel-Mottaleb M, Abdel-Mottaleb Y. In search for effective and safe drugs against sars-cov-2: part I] simulated interactions between selected nutraceuticals, ACE2 enzyme and s protein simple peptide sequences. ChemRxiv. 2020.
  16. Priel A, Silberberg SD. Mechanism of ivermectin facilitation of human P2X4 receptor channels. J Gen Physiol. 2004; 123(3): 281–293.
  17. Njoo FL, Hack CE, Oosting J, et al. C-reactive protein and interleukin-6 are elevated in onchocerciasis patients after ivermectin treatment. J Infect Dis. 1994; 170(3): 663–668.
  18. Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008; 57(11): 524–529.
  19. Steinhoff M, Vocanson M, Voegel JJ, et al. Topical ivermectin 10 mg/g and oral doxycycline 40 mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments. Adv Ther. 2016; 33(9): 1481–1501.
  20. de Melo GD, Lazarini F, Larrous F, et al. Anti-COVID-19 efficacy of ivermectin in the golden hamster. bioRxiv. 2020.
  21. Babalola OE, Bode CO, Ajayi AA, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM. 2021 [Epub ahead of print]: hcab035.
  22. Soto-Becerra P, Culquichicón C, Hurtado-Roca Y, et al. Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru. medRxiv. 2020.
  23. Elgazzar A, Hany B, Youssef S, et al. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Research Square. 2020.
  24. Niaee M, Gheibi N, Namdar P, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial. Research Square. 2020.
  25. Hashim H, Maulood M, Rasheed A, et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv. 2020.
  26. Roy R, Pattadar C, Raj R, et al. Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in eastern india. J Pharm Pharm Sci. 2021; 24: 343–350.
  27. Rajter JC, Sherman MS, Fatteh N, et al. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study. Chest. 2021; 159(1): 85–92.
  28. Khan SI, Khan SI, Debnath CR, et al. Ivermectin treatment may improve the prognosis of patients with COVID-19. Arch Bronconeumol (Engl Ed). 2020; 56(12): 828–830.
  29. Gorial F, Mashhadani S, Sayaly H, et al. Effectiveness of ivermectin as add-on therapy in COVID-19 management (pilot trial). medRxiv. 2020.
  30. Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021; 103: 214–216.
  31. Spoorthi V, Sasank S. Utility of ivermectin and doxycycline combination for the treatment of SARS-CoV2. Int Arch Integrated Med. 2020; 7(10): 177–182.
  32. Chachar AZ, Khan KA, Asif M, et al. Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients. International Journal of Sciences. 2020; 9(09): 31–35.
  33. Camprubí D, Almuedo-Riera A, Martí-Soler H, et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS One. 2020; 15(11): e0242184.
  34. Rahman M, Iqbal S, Islam M, et al. Comparison of viral clearance between ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients. Journal of Bangladesh College of Physicians and Surgeons. 2020: 5–9.
  35. Padhy BM, Mohanty RR, Das S, et al. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. J Pharm Pharm Sci. 2020; 23: 462–469.
  36. Budhiraja S, Soni A, Jha V, et al. Clinical profile of first 1000 COVID-19 cases admitted at tertiary care hospitals and the correlates of their mortality: an indian experience. medRxiv. 2020.
  37. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002; 42(10): 1122–1133.
  38. Kircik LH, Del Rosso JQ, Layton AM, et al. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016; 15(3): 325–332.
  39. Gardon J, Gardon-Wendel N, Kamgno J, et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997; 350(9070): 18–22.
  40. National Institutes of Health. The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Ivermectin for the Treatment of COVID-19 [Online]. NIH COVID-19 Treatment Guidelines. 2021 Jan 14. https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section_106.pdf (5.03.2021).
  41. Merck Statement on Ivermectin use During the COVID-19 Pandemic [Online]. 2021 Feb 4. http://www.merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic/ (5.03.2021).
  42. López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. JAMA. 2021; 325(14): 1426–1435.
  43. Takano R, Sugano K, Higashida A, et al. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res. 2006; 23(6): 1144–1156.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl